Fraunhofer Institute For Translational Medicine And Pharmacology ITMP — Clinical Trial Site

27 Registered trials

14 Currently recruiting

Organisation

Fraunhofer Institute For Translational Medicine And Pharmacology ITMP

Location

Frankfurt Am Main, Germany

Identifier

ORG-100044106

Address

Theodor-Stern-Kai 7, Sachsenhausen, 60596, Germany

Departments

-
#303
#304
#3104: Fraunhofer Institute For Translational Medicine And Pharmacology ITMP
#40367
1102: Fraunhofer Institute For Translational Medicine And Pharmacology ITMP
2152: Fraunhofer Institute For Translational Medicine And Pharmacology ITMP
Allergology and Immunology
ECTU
Fraunhofer Institute for Translational Medicine and Pharmacology ITMP (IA)
Fraunhofer-Institut für Translationale Medizin und Pharmakologie
Fraunhofer-Institut für Translationale Medizin und Pharmakologie ITMP
Fraunhofer-Institute for Translational Medicine and Pharmacology ITMP
Immunologie und Allergologie IA
Immunology and Allergology IA c/o Charité - Universitätsmedizin Berlin
Institute for Translational Medicine and Pharmacology ITMP
Internal Medicine, Rheumatology
ITMP
ITMP Clinical Research
Medizinische Klinik 1
N/A
Neurology

Clinical trials at this site (27)

Search interface

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy… Pending

2025-521145-24-01 Active Idiopathic Inflammatory Myopathy including derma 9
AN OUTPATIENT, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, CROSS-OVER STUDY OF THE EFFICACY OF ARS-2 IN PATIENTS WITH CHRONIC SPONTANEOU… Pending

2025-521930-27-00 Chronic Spontaneous Urticaria (CSU) 4
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P… Pending

2025-522471-28-00 psoriatic arthritis (PsA) 5
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Recruiting

2025-522878-36-00 Chronic Spontaneous Urticaria 5 2026-04-20
A study to learn if bimekizumab given in different ways is safe and moves similarly throughout the body over time in adults Recruiting

2025-522782-30-00 CCI 3 2026-04-07
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis Recruiting

2025-520721-21-00 Rheumatoid Arthritis 4 2025-10-20
Phase 3 Study of Barzolvolimab in Participants with Cold Induced Urticaria and Symptomatic Dermographism Recruiting

2025-522583-32-00 Cold-Induced Urticaria and Symptomatic Dermographism 5 2026-04-13
An open label, phase I/II study investigating the safety and efficacy of a CD3/CD20 bispecific T-cell engager therapy in patients with activ… Recruiting

2025-522853-21-01 Active, treatment refractory, ANCA-IgG-positive associa 9 2026-02-27
An open label, phase I/II study investigating the safety and efficacy of the bispecific T-cell engaging antibody cizutamig (BCMAxCD3) in pat… Recruiting

2025-522857-20-00 Severe, treatment refractory primary Sjögren’s disease 9 2026-01-22
A Phase 1 Study of the Safety and Preliminary Efficacy of CTX112 in Adult Subjects With Refractory Autoimmune Disease. Recruiting

2024-518528-54-00 Active systemic lupus erythematosus (SLE), systemic scl 1 2025-12-02
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in partici… Recruiting

2024-516219-25-00 psoriatic arthritis 5 2025-03-25
A placebo-controlled, single-blind, phase I study in healthy volunteers and patients with Rheumatoid Arthritis with ABO21009 Recruiting

2024-517547-31-00 Rheumatoid Arthritis 1 2025-01-31
A clinical trial to learn about the effects of YTB in people with difficult to treat active systemic lupus erythematosus (SLE), or active k… Recruiting

2023-510150-17-00 Active, refractory systemic lupus erythematosus (SLE), 4 2024-12-11
A clinical trial to learn about the effects of YTB323 in people with difficult to treat severe diffuse cutaneous systemic sclerosis (dcSSc) Recruiting

2023-510380-34-00 Diffuse cutaneous systemic sclerosis (dcSSc) 4 2024-12-10
Long-term safety and tolerability of cenerimod in adults with systemic lupus erythematosus (OPUS OLE) Recruiting

2024-514354-67-00 Systemic lupus erythematosus 5 2024-11-01
Prospective, multicentre, open-label clinical trial on the effect of GUSelkumab on the resolution of ultrasound-proven ENThEsitis in patient… Recruiting

2024-512459-19-00 Psoriatic arthritis 6 2024-09-13
Study of BLU-808 in Chronic Inducible Urticaria and Chronic Spontaneous Urticaria Ended

2024-520031-33-00 Chronic Inducible Urticaria and Chronic Spontaneous Urt 4 2025-09-16
A clinical trial to learn about the effects of YTB323 in people with difficult-to-treat severe inflammatory myopathies (IIM) Ended

2024-514137-38-00 Severe refractory idiopathic inflammatory myopathies (I 4 2025-02-04
A study to learn how well bimekizumab works and how safe it is in adults with psoriatic arthritis Ended

2024-511738-11-00 Psoriatic arthritis 5 2024-12-18
A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended

2024-513208-32-00 Chronic Spontaneous Urticaria 5 2024-12-16
A research study to evaluate the efficacy and safety of cenerimod in subjects suffering from systemic lupus erythematosus Ended

2024-515871-37-00 Moderate to severe systemic lupus erythematosus 5 2024-10-24
Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis Ended

2023-510127-30-00 Relapsing Remitting Multiple Sclerosis (RRMS) 1 2024-04-17
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis Ended

2022-502994-40-00 Rheumatoid Arthritis 4 2023-09-04
A study to characterize the pharmacokinetic profile of norucholic acid (NCA) in patients with primary sclerosing cholangitis (PSC) Ended

2023-507027-37-00 Primary Sclerosing Cholangitis (PSC) 3 2023-07-20